BillionToOne's Single-Molecule Counter Is a Wedge Into Prenatal and Oncology Panels

For parents facing a high-risk prenatal screening result, the path forward is often a stark choice between invasive, potentially risky diagnostic procedures or waiting for a birth to confirm a diagnosis. BillionToOne’s clinical bet is that its technology can shrink that diagnostic gray area, offering more definitive answers from a simple maternal blood draw. The company’s Quantitative Counting Templates (QCT) platform, which its founders developed at Stanford, is engineered to count individual DNA molecules, a resolution it claims improves the sensitivity of cell-free DNA diagnostics by a thousandfold [Workable, 2026]. This single-molecule precision is the technical core of its two commercial pillars: the UNITY prenatal screen and the Northstar oncology liquid biopsy.

Since its 2016 founding, BillionToOne has navigated the long, capital-intensive road of clinical validation, regulatory strategy, and payer reimbursement to reach a notable milestone for a diagnostics company: public market viability. It went public on Nasdaq in November 2025, raising $273 million at a $5.8 billion valuation [Forbes, Nov 2025]. More telling than the IPO itself are the financial metrics that followed. The company finished 2025 with $305.1 million in revenue, doubling its year-over-year performance, and reported its first quarterly net income of $4.4 million in Q4 2025 [stocktitan.net, 2026] [simplywall.st, 2026]. Its annualized revenue run rate hit $384 million by the end of that quarter, with guidance for 2026 raised to between $430 million and $445 million [Yahoo Finance, 2026].

The single-molecule wedge

Traditional next-generation sequencing (NGS) for cell-free DNA analysis works by sampling and amplifying fragments, a process that can introduce noise and limit sensitivity, especially for rare variants. BillionToOne’s QCT platform uses synthetic DNA templates to physically tag individual DNA molecules before amplification. This allows the lab to count original molecules directly, reducing required sequencing depth and, the company argues, lowering costs while boosting accuracy [LinkedIn]. The clinical translation of this method is a portfolio of blood tests that aim to detect signals others might miss.

In prenatal care, its flagship UNITY Screen is a non-invasive prenatal test (NIPT) that goes beyond the standard panel for chromosomal aneuploidies like Down syndrome. It is billed as the first and only NIPT that can also screen for single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and certain hemoglobinopathies from maternal blood alone, without needing a paternal sample [Zoominfo]. The company celebrated conducting its one-millionth UNITY test in March 2025 [BillionToOne, Mar 2025]. In oncology, the Northstar tests are tumor-informed, circulating tumor DNA (ctDNA) assays designed for cancer detection and monitoring treatment response [Bitget].

From Stanford lab to public markets

The company’s trajectory is deeply tied to its founding technical team. CEO Oguzhan Atay and President/CTO David Tsao, both Stanford PhDs, developed the QCT approach as graduate students and spun it into BillionToOne in 2016 [Y Combinator]. They were later joined by co-founder Sukrit Silas, who led experimental test development and clinical trials [Speakerpedia, 2026]. This continuity provided a through-line from fundamental research to commercial execution, a journey funded by nearly $375 million in private capital before the IPO [Forbes, Nov 2025].

Major investors include WestCap, Willoughby Capital, and Premji Invest. The funding history shows a company that raised progressively larger rounds as it scaled its commercial lab operations.

2019 Seed | 15 | M USD
2021 Series B | 55 | M USD
2022 Series D+ | 48.5 | M USD
2024 Series D | 130 | M USD
2025 IPO | 273 | M USD

The competitive landscape and reimbursement reality

BillionToOne operates in two fiercely competitive markets. In prenatal testing, it faces giants like Natera, Illumina, and LabCorp, as well as large diagnostic players like Quest Diagnostics and Roche. In oncology liquid biopsy, it competes with Exact Sciences, Guardant Health, and Natera again. Its wedge is technological specificity, but commercial success hinges on more than a better mousetrap.

• Reimbursement as moat. The company generates revenue primarily through test volume reimbursed by commercial and government payers. Its improving gross margin, reaching 71% in Q4 2025 [stocktitan.net, 2026], suggests it is gaining traction in securing favorable payer contracts, a critical and non-trivial hurdle in diagnostics.
• The platform scalability question. A core promise of QCT is that the same underlying platform can be adapted to multiple test types, theoretically improving margins over time. The expansion from UNITY to Northstar, and the launch of confirmatory tests like Unity Confirm, tests this thesis. The risk is that each new clinical application requires its own costly validation studies and payer negotiations.
• Execution versus incumbency. While BillionToOne has posted impressive growth, its competitors are entrenched, with vast sales forces and long-standing payer relationships. The company’s ability to continue taking share, particularly in oncology where clinician adoption cycles are long, will be a key monitorable.

The company’s strong cash position of $496 million at the end of 2025, against only $50 million in term debt [Yahoo Finance, 2026], provides a substantial runway to navigate these challenges.

The patient at the center of the panel

Ultimately, BillionToOne’s technology is aimed at specific, high-stakes patient populations. The UNITY Screen serves expectant parents, particularly those with family histories of single-gene disorders or those flagged as higher risk from earlier screenings. The ability to screen for conditions like cystic fibrosis from a blood test represents a significant reduction in anxiety and physical risk compared to procedures like chorionic villus sampling or amniocentesis.

The standard of care today for single-gene disorder screening often involves carrier testing of the parents prior to pregnancy, or invasive diagnostic testing after a pregnancy is underway if a risk is known. For many, these disorders are only discovered after birth. BillionToOne’s proposition is to move that detection window earlier and non-invasively. In oncology, the Northstar tests are designed for patients with diagnosed cancers, aiming to provide a more sensitive tool for detecting minimal residual disease and monitoring the effectiveness of therapy, a process that currently relies on a mix of imaging, tissue biopsies, and less sensitive blood tests.

The next twelve months will test whether this patient-centric, platform-driven model can sustain its growth trajectory post-IPO. Key milestones will be the revenue growth against its elevated 2026 guidance and any new clinical data or regulatory clearances that expand the utility of its single-molecule counting approach into new disease states.

Sources

1. [Forbes, Nov 2025] How A Turkish Immigrant Engineered A Successful Diagnostics Startup IPO | https://www.forbes.com/sites/amyfeldman/2025/11/06/how-a-turkish-immigrant-engineered-a-successful-diagnostics-startup-ipo-billiontoone/
2. [BillionToOne, Mar 2025] BillionToOne Celebrates Major Milestone: 1 Million UNITY Tests | https://www.billiontoone.com/news-media/billiontoone-celebrates-major-milestone-1-million-unity-tests
3. [Yahoo Finance, 2026] Financial data and guidance | https://finance.yahoo.com
4. [stocktitan.net, 2026] Financial results reporting | https://stocktitan.net
5. [simplywall.st, 2026] Earnings data | https://simplywall.st
6. [Zoominfo] Company and product overview | https://www.zoominfo.com/c/billiontoone-inc/442175124
7. [LinkedIn] Technology description | https://www.linkedin.com/company/billiontoone
8. [Workable, 2026] Technology claim | https://workable.com
9. [Bitget] Oncology product description | https://www.bitget.com/stock/nasdaq-blln/what-is
10. [Y Combinator] Founder background | https://www.ycombinator.com/blog/billiontoone
11. [Speakerpedia, 2026] Co-founder role | https://speakerpedia.com
12. [PRNewswire, Jun 2024] Series D funding announcement | https://www.prnewswire.com/news-releases/leading-molecular-diagnostics-company-billiontoone-raises-130-million-in-oversubscribed-series-d-funding-over-1b-valuation-302179324.html